<DOC>
	<DOCNO>NCT00374140</DOCNO>
	<brief_summary>This phase II , two-stage , open-label , single-agent study experimental drug RAD001 ( everolimus ) patient previously treat small cell lung cancer . RAD001 administer orally dose 10 mg daily .</brief_summary>
	<brief_title>Phase II Trial RAD001 ( Everolimus ) Previously Treated Small Cell Lung Cancer</brief_title>
	<detailed_description>This phase II , two-stage , open-label , single-agent study experimental drug RAD001 ( everolimus ) patient previously treat small cell lung cancer . Patients may receive 2 prior chemotherapy regimens small cell lung carcinoma , prior therapy m-TOR inhibitor . RAD001 administer orally dose 10 mg daily . A cycle define 3 week study drug administration , patient tumor measurement every 2 cycle . Study participation continue disease progression intolerable toxicity . In addition , patient consent , archival tumor tissue ( paraffin block original biopsy ) collect research purpose .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Cytologically histologically confirm small cell carcinoma lung progress post firstline therapy . Mixed small nonsmall cell tumor exclude . 2 . Prior chemotherapy small cell carcinoma . Up 2 prior chemotherapy regimens small cell lung carcinoma allow . No prior therapy mTOR inhibitor ( e.g . CCI779 ) . 3 . Unidimensionally measurable disease ( RECIST criterion ) . If site measurable disease previously irradiate area , patient must document progression disease area . 4 . ECOG performance status 02 . 5 . A minimum 4 week elapse prior chemotherapy . Patients must fully recover effect prior surgery radiation therapy anticancer therapy , include immunotherapy investigational agent . 6 . No progressive brain metastasis . Brain metastases previously treat surgery and/or radiation . 7 . Patients prior malignancy least 3 year diseasefree survival . Prior curatively treat squamous cell basal carcinoma skin situ cervical cancer situ malignancy allow . 8 . No coexist medical condition would preclude full compliance study . 9 . Required laboratory value ( obtain &lt; 1 week prior enrollment ) : ANC &gt; /= 1500/mm³ Platelets &gt; /= 100,000/mm³ AST ALT ≤ 3 x ULN ( upper limit normal ) . In patient liver metastasis AST ALT &lt; 5 x ULN . Total bilirubin 1.5 x ULN ( upper limit normal ) . 10 . Age &gt; /= 18 year capacity give inform consent . 11 . Patients advise discontinue drug interact CYP3A4 ( see list example Table 3.1 full protocol ) , medically safe . 12 . All patient must give sign , informed consent prior registration study . 1 . Prior treatment investigational agent within precede 4 week . 2 . Other concurrent severe and/or uncontrolled medical disease could compromise participation study ( i.e. , uncontrolled diabetes , uncontrolled hypertension , severe infection , severe malnutrition , unstable angina , congestive heart failure New York Heart Association Class III IV , ventricular arrhythmia active ischemic heart disease , myocardial infarction within six month , chronic liver renal disease , active upper GI tract ulceration ) . 3 . A known history HIV seropositivity . 4 . Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption RAD001 ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) . 5 . Patients active , bleed diathesis anticoagulation ( except low dose warfarin ) . 6 . Pregnant lactate woman exclude study agent use study may teratogenic fetus information excretion agent metabolites breast milk . 7 . Women childbearing potential sexually active male must agree use accepted effective method contraception ( hormonal barrier method , abstinence ) prior study entry duration study . 8 . Patients chronic systemic glucocorticoid immunosuppressant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>small cell</keyword>
	<keyword>lung</keyword>
</DOC>